Filing Details

Accession Number:
0001104659-21-020672
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-02-11 16:06:15
Reporting Period:
2021-02-09
Accepted Time:
2021-02-11 16:06:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886163 Ligand Pharmaceuticals Inc LGND Pharmaceutical Preparations (2834) 770160744
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1442372 L Stephen Sabba Dorset Management Corp
485 Underhill Blvd Suite 205
Syosset NY 11791
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-02-09 7,335 $10.12 31,766 No 4 M Direct
Common Stock Acquisiton 2021-02-09 7,335 $12.53 39,101 No 4 M Direct
Common Stock Disposition 2021-02-09 556 $208.00 38,545 No 4 S Direct
Common Stock Disposition 2021-02-09 14,114 $208.55 24,431 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-02-09 7,335 $0.00 7,335 $10.12
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2021-02-09 7,335 $0.00 7,335 $12.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2021-06-01 No 4 M Direct
0 2022-05-31 No 4 M Direct
Footnotes
  1. These securities, as represented in Column 5, include a grant of 831 restricted shares approved by the Board of Directors of the Company at the 2020 Meeting, which shares were previously reported on a Form 4 for this Reporting Person filed on June 12, 2020, and are included on this Form 4 only to report that they will vest in full within six (6) months from the date hereof.
  2. These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2011 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 6, 2011.
  3. These securities, as represented in Column 5, were acquired by a grant of 7,335 shares approved by the Board of Directors of the Company at the 2012 Meeting and are fully vested and exerciseable as more fully described on a Form 4 for this Reporting Person filed on June 4, 2012.